

**JCG INVESTMENT HOLDINGS LTD.**  
(formerly known as China Medical (International) Group Limited)  
(Company Registration No. 200505118M)

---

**PROPOSED ACQUISITION OF BRAND X LAB PTE. LTD. – RECEIPT OF LISTING AND  
QUOTATION NOTICE**

---

**1. INTRODUCTION**

- 1.1 The Board of Directors (“**Directors**”) of JCG Investment Holdings Ltd (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the announcement made by the Company on 12 March 2019 (“**Previous Announcement**”) in relation to the acquisition of 100.00% equity interest in Brand X Lab Pte. Ltd. (“**Proposed Acquisition**”).
- 1.2 Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Previous Announcement. Any reference to the time of day and date herein shall be a reference to Singapore time and date, respectively.

**2. LISTING AND QUOTATION NOTICE**

- 2.1 The Directors wish to announce that the Company’s Sponsor (as defined below) has for and on behalf of the Company, on 4 April 2019, obtained the listing and quotation notice (the “**LQN**”) from the SGX-ST in respect of the listing and quotation of:
- A. 1,861,111,111 new ordinary shares in the capital of the Company (“**Consideration Shares**”) at an issue price of S\$0.0018 each; and
- B. up to 310,185,185 new ordinary shares in the capital of the Company (“**Warrant Shares**”) to be issued pursuant to the exercise of 310,185,185 unlisted warrants (“**Warrants**”) in the Company, each Warrant carrying the right to convert into one (1) Warrant Share in the capital of the Company at an exercise price of S\$0.0018 for each Warrant Share,
- to be issued to Tan Suying (the “**Vendor**”) pursuant to a sale and purchase agreement entered into by the Company and the Vendor on 11 March 2019 for the Proposed Acquisition.
- 2.3 Please note that the LQN is not to be taken as an indication of the merits of the Proposed Acquisition, the Consideration Shares, Warrant Shares, Warrants, the Company, its subsidiaries and their securities.

**BY ORDER OF THE BOARD**

**4 April 2019**

---

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**") for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg))